Next Article in Journal
An Index for Quantitative Evaluation of the Mixing in Ethanol Precipitation of Traditional Chinese Medicine
Next Article in Special Issue
Introducing a Novel Biorelevant In Vitro Dissolution Method for the Assessment of Nicotine Release from Oral Tobacco-Derived Nicotine (OTDN) and Snus Products
Previous Article in Journal
Study on the Stability of Antibiotics, Pesticides and Drugs in Water by Using a Straightforward Procedure Applying HPLC-Mass Spectrometric Determination for Analytical Purposes
Previous Article in Special Issue
A Sensitive LC–MS/MS Method for the Quantification of 3-Hydroxybenzo[a]pyrene in Urine-Exposure Assessment in Smokers and Users of Potentially Reduced-Risk Products
 
 
Article

1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption

ABF Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstr. 5, 82152 Planegg, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Fadi Aldeek
Separations 2021, 8(10), 180; https://doi.org/10.3390/separations8100180
Received: 13 August 2021 / Revised: 30 September 2021 / Accepted: 2 October 2021 / Published: 9 October 2021
Over the past decade, new emerging tobacco and nicotine-delivery products have changed the tobacco landscape. Especially, electronic cigarettes (ECs) have been suggested to be considered for tobacco harm reduction, reinforcing the need to identify novel biomarkers of exposure (BoE) specific to the EC use as this would complement exposure assessment and product compliance monitoring. Therefore, a sensitive LC-MS/MS method for the quantification of 1,2-propylene glycol (PG) and glycerol (G), the main e-liquid constituents, was established. PG and G were analyzed in plasma and urine samples from a clinical study comparing five nicotine product user groups, users of combustible cigarettes (CC), electronic cigarettes (EC), heated tobacco products (HTP), oral tobacco (OT), and oral/dermal nicotine delivery products (used for nicotine replacement therapy, NRT) with a control group of non-users (NU). Data demonstrate significantly elevated PG levels in urine and plasma in EC users compared to users of CC, HTP, NRT, OT as well as NU. In addition, PG in plasma and urine of vapers significantly correlated with nicotine (plasma) and total nicotine equivalents (urine), biomarkers reflecting product consumption, emphasizing the high specificity of PG as a BoE for EC consumption. We therefore suggest the use of PG as BoE in urine and/or plasma in order to monitor EC use compliance in exposure assessments. View Full-Text
Keywords: propylene glycol; electronic cigarette; biomarker of exposure; compliance marker propylene glycol; electronic cigarette; biomarker of exposure; compliance marker
Show Figures

Graphical abstract

MDPI and ACS Style

Burkhardt, T.; Pluym, N.; Scherer, G.; Scherer, M. 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption. Separations 2021, 8, 180. https://doi.org/10.3390/separations8100180

AMA Style

Burkhardt T, Pluym N, Scherer G, Scherer M. 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption. Separations. 2021; 8(10):180. https://doi.org/10.3390/separations8100180

Chicago/Turabian Style

Burkhardt, Therese, Nikola Pluym, Gerhard Scherer, and Max Scherer. 2021. "1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption" Separations 8, no. 10: 180. https://doi.org/10.3390/separations8100180

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop